The Premier Consulting Blog

MAY 31, 2023

While the type, number, and design of these studies vary based on product-specific characteristics, IND-enabling packages submitted to the FDA generally include key information about the pharmacology, pharmacokinetics, and toxicology of the product. All these studies need to be performed under GLP.

Packaging 52

Packaging Pharmacokinetics Small Molecule Clinical Trials 52

The Premier Consulting Blog

JULY 31, 2024

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways. Author: Jayesh Patel , Principal Scientist, Pharmacokinetics

Clinical Pharmacology 52

Clinical Pharmacology Drug Development Pharmacokinetics Drugs 52

The Premier Consulting Blog

APRIL 15, 2024

In this blog, we will go into more detail about the unwritten nonclinical requirements for the PIND meeting.

FDA 52

FDA Pharmacokinetics Laboratories FDA Approval 52

The Premier Consulting Blog

SEPTEMBER 11, 2024

The 505(b)(2) submission for Bendeka included a complete chemistry, manufacturing, and controls (CMC) package, but relied on the drug master file (DMF) for Treanda. The overall development strategy for GT123 was to include a complete CMC package. daily versus four times daily dosing). Human factors.

Drugs 52

Drugs Clinical Pharmacology Packaging Small Molecule 52

The Premier Consulting Blog

AUGUST 8, 2024

For example, pharmacokinetic (PK) data from a comparative BA study and PK modeling approaches (e.g., Typically, new drug development under the 505(b)(2) pathway requires less capital and time and has a higher success rate versus the 505(b)(1) pathway, where the Sponsor develops safety and effectiveness information from scratch.

Drugs 52

Drugs Pharmacokinetics FDA Production 52

Practical Cheminformatics

JANUARY 8, 2024

Gotta be SAFE: A New Framework for Molecular Design [link] A blog post by Edward Williams from Terray Therapeutics introduced Contrastive Optimization for Accelerated Therapeutic Inference (COATI). In each example, the authors use a modified version of their open source package MolPAL to design molecules with a specified selectivity profile.

Drugs 139

Drugs Small Molecule Bioinformatics Packaging 139

Codon

APRIL 2, 2023

Read Inhalable nanoparticles, packaged with mRNA or CRISPR systems, efficiently edit lung cells. Large-scale purification of functional AAV particles packaging the full genome using short-term ultracentrifugation with a zonal rotor. Nature Biotechnology. Ricciardi M.J. Science Translational Medicine. Gene Therapy.

DNA 52

DNA RNA Engineering Licensing 52